SCHEMBL26075925

SCHEMBL26075925

CCOc1ccc(-c2ccc(-c3cc(C(=O)O)c4cc(C)ccc4n3)cc2F)c(F)c1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 7/20 0.61
▸ SMN1; SMN2 Q16637 5/20 0.61
▸ HSD17B10 Q99714 3/20 0.61
▸ MEN1 O00255 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ ALDH1A1 P00352 4/20 0.56
▸ LMNA P02545 3/20 0.56
▸ HPGD P15428 2/20 0.56
▸ NPC1 O15118 1/20 0.56
▸ RAB9A P51151 1/20 0.56
▸ CYP1A2 P05177 1/20 0.55
▸ TSHR P16473 1/20 0.55
▸ TP53 P04637 2/20 0.53
▸ MAPT P10636 5/20 0.51
▸ MAPK1 P28482 1/20 0.51
▸ TDP1 Q9NUW8 1/20 0.51
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ DHODH Q02127 7/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075296 0.94 KDM4E (0.59) KDM4ESMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL23590289 0.91 KDM4E (0.62) KDM4ESMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL23590135 0.87 KDM4E (0.58) KDM4ESMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL26075977 0.87 DHODH (0.53) KDM4ESMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL27015272 0.86 DHODH (0.57) KDM4ESMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL23590271 0.85 KDM4E (0.72) KDM4ESMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL23590076 0.85 DHODH (0.63) KDM4ESMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL29997485 0.85 DHODH (0.60) KDM4ESMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL23590091 0.85 DHODH (0.60) KDM4ESMN1; SMN2HSD17B10MEN1KMT2A
SCHEMBL26075413 0.85 KDM4E (0.42) KDM4ESMN1; SMN2HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE OHIO STATE INNOVATION FOUNDATION (US) 2024-01-18 — — US disclosed
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD KDM4E 1396/4885SMN1; SMN2 3677/4885HSD17B10 130/4885
US-20240018108-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE DHODH, DLD, FAH KDM4E 580/4885SMN1; SMN2 3516/4885HSD17B10 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback